DSC02436.JPG
 
 

.01

about us

Preventable blindness, in the form of glaucoma, diabetic eye diseases, and age-related macular degeneration persist in our families and friends. It is the cause of over $139B in economic burden to the US economy alone, and over 80 million patients have preventable blindness diseases here in the US.

OUr future is in sight

BioHealthWays is determined to fight diseases by delivering focused, next-generation therapies.

We are a company whose success will be based on enabling large pharmaceutical partners to achieve the impossible: prevention and cure of  debilitating diseases. We harness the possibilities in new biologic and nucleic acid therapies being developed every day, and participate in the exciting commitment to fighting preventable blindness.

Customized Drug Delivery, enabled by polymeric means, is the key to drugs with better safety, efficacy, toxicology, and release profiles. BioHealthWays is building prodrugs that localize and enable protein-based therapies. Together with partners, we can change the way diseases are treated today. We are, in short, delivering value through innovation.

Drug delivery system for ocular biologic and pharmaceutical therapeutics:

  • neo-vascular conditions (diabetic and age-related)
  • glaucoma
  • inflammatory eye & trauma

We will work with you and out-license our drug delivery platform, creating best-in-class product attributes:

  • Premise: Ocular indications require specialized drug delivery mechanisms to provide effective dosing for long enough
  • Insight: BioHealthWays has a drug delivery system designed to achieve sustained release of biologics for >6 months intraocularly
  • Result: Working with leading institutions, BioHealthWays co-formulates products to achieve significant holistic competitive advantages
 
 

02.


Our ManagemeNT

Brian Pan

Chief Executive Officer

Picture4.png

Brian is the cofounder and CEO of BioHealthWays. Prior to BioHealthWays, Brian was a strategic advisor at Galt & Company, a firm that delivers high value strategies and implements operating conditions, to exceed customer and shareholder expectations. He has supported notable divestitures, acquisitions, and resource allocation strategies across corporate functional areas. Before Galt & Company, Brian worked at Accenture Strategy. Fortune 500 clients include: Coca-Cola, Caterpillar, Abbott Medical Optics, Bristol Myers Squibb, Fiat-Chrysler Automobiles, AT&T, Pitney Bowes.

Selected Cases:

Secondments:
Johannesburg, South Africa (12 months), Dubai, UAE (4 months), Jeddah, Saudi Arabia (4 months), Geneva, Switzerland (4 months), Istanbul, Turkey (12 months), Various intermittent locations Domestic and Global

Memberships:

Board, Columbia Engineering Young Alumni

Education:

B.S. IEOR: Engineering and Management Systems, Economics, Technical Entrepreneurship, Columbia University Fu Foundation School of Engineering and Applied Science with selected studies at Columbia Business School (MBA)

 


Dr. David Pan

President and Chief Technology Officer

David Headshot.png

David is co-founder, President, and Chief Technology/Business Officer  of BioHealthWays, Inc. David brings a unique combination of corporate commercialization and innovation as well as patent expertise. Having served at Xerox Corporation for over 32 years in various senior roles at the Office of General Counsel as well as Offices of Corporate Innovation and Research & Development, David has nearly 100 patents to his name, several of which have been commercialized and/or out-licensed.  Products utilizing his technology include: e-ink as used in the Kindle reader, various technologies in Xerox printers, and biomaterials in biomedical imaging. Through his innovations, he has delivered over $100M+ in customer value. David is an expert in product delivery of hydrogels, polymers, block copolymers, elastomer nano-composites, polymer chemistry, physics, engineering, and structure-property relationships. He has unusual expertise as an inventor and patents infringement investigator, and is called as an expert witness for general IP defense expertise in U.S. court investigations.

David is a member of various professional societies, including American Chemical Society, American Physical Society, and Materials Research Society. He has received numerous corporate awards and session chairmanships. He has written over 25 journal-accepted publications, and given multiple public talks at research organizations, professional societies, and conferences worldwide.

Research Interests:

  • Hydrogels, Polymers, Block Copolymers, polymer chemistry
  • Elastomer nano-composites
  • Physics, Engineering, Structure-property relationships

Education:

Ph.D. Chemical Engineering, University of Wisconsin-Madison

B.Eng. Chemical Engineering, National Taiwan University


SCIENCE ADVISORS


BUSINESS ADVISORS

 
DSC00907.JPG
 

.03

Pipeline

A biodegradable intravitreal drug delivery system

A biodegradable intravitreal drug delivery system

A typical applicator

A typical applicator


 

Disposable Prefill Syringe Cartridge & Motorized Applicator Wand

 

2020+

Smart motorized applicator wand with standard disposable prefilled syringes.

Syringes capable of delivering: implants, liquids, gels, & other

 

 

Intravitreal Biologic Extended release

wet Advanced Macular Degeneration

Diabetic Retinopathy

Retinal Vein Occlusion

2022+

Developing the next generation drug delivery systems for anti-VEGF therapy

Prototype / Preclinical

 

 

Intravitreal biologic extended release

Glaucoma

2024+

Developing the next generation drug delivery systems for glaucoma treatment

Prototype / Preclinical

 

 

INTRAVITREAL BIOLOGIC EXTENDED RELEASE

Eye Trauma and Inflammation

2024+

Developing the next generation drug delivery systems for traumatic eye injury and retinal inflammation

Prototype / Preclinical

 
 
 
 

.05

CONTACT US

 

We like hearing from you!